Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial

Area of Science:

• Neurology
• Immunology
• Clinical Trials

Background:

• Multifocal motor neuropathy (MMN) is an immune-mediated disorder causing progressive limb weakness.
• Intravenous immunoglobulin (IVIg) treatment improves muscle strength in MMN patients.
• Adjunctive immunosuppressants are anecdotally suggested for MMN management.

Purpose of the Study:

• To evaluate the safety and efficacy of Mycophenolate Mofetil (MMF) as an adjunctive therapy for MMN patients on maintenance IVIg.
• To determine if MMF allows for a significant reduction in IVIg dosage.
• To assess MMF's impact on muscle strength, functional status, and anti-GM1-IgM titers.

Main Methods:

• A randomized controlled trial involving MMN patients responding to IVIg.
• Patients received either MMF or placebo alongside IVIg for 1 year.
• IVIg doses were reduced stepwise after 3 months of adjunctive treatment.
• Muscle strength, functional status, and anti-GM1-IgM titers were primary and secondary outcome measures.

Main Results:

• Only one patient in the MMF group achieved the primary endpoint of 50% IVIg dose reduction.
• No significant difference in IVIg reduction was observed between MMF and placebo groups after 12 months.
• MMF treatment was safe, with no drug toxicity or significant disease progression observed.
• Muscle strength, functional scores, and anti-GM1-IgM titers did not significantly change in either group.

Conclusions:

• Adjunctive treatment with Mycophenolate Mofetil (MMF) at 1g twice daily is safe for MMN patients receiving IVIg.
• MMF does not alter the disease course of MMN.
• MMF does not permit a significant reduction in IVIg dosage for MMN patients.